5 mg prednisone    (DrugBank: Prednisone)

1 disease
IDDisease name (Link within this page)Number of trials
44Wegener granulomatosis2

44. Wegener granulomatosis    [ 84 clinical trials,   88 drugs,   (DrugBank: 22 drugs),   13 drug target genes,   37 drug target pathways]
Searched query = "Wegener granulomatosis", "Multiple vasculitis granulomatous disease", "Granulomatosis with polyangiitis"
The queries were searched in Public_title, Scientific_title, and Condition. Export date: 03/15/2021. Trials are sorted by Date_enrollment from most recent to oldest in the table.
2 / 84 trials found
No.TrialIDDate_
enrollment
Date_
registration
Public_titleScientific_titleConditionInterventionPrimary_
sponsor
Secondary_
sponsor
Recruitment_
Status
Inclusion_
agemin
Inclusion_
agemax
Inclusion_
gender
Target_
size
PhaseCountries
1NCT01933724
(ClinicalTrials.gov)
February 17, 201428/8/2013The Assessment of Prednisone In Remission Trial (TAPIR) - Patient Centric ApproachThe Assessment of Prednisone In Remission Trial (TAPIR) - Patient Centric ApproachGranulomatosis With Polyangiitis;Wegener Granulomatosis;VasculitisDrug: 5 mg prednisone;Drug: 0 mg prednisoneUniversity of South FloridaNational Institutes of Health (NIH);National Heart, Lung, and Blood Institute (NHLBI);National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS);Office of Rare Diseases (ORD);National Center for Advancing Translational Science (NCATS);Rare Diseases Clinical Research NetworkActive, not recruiting18 YearsN/AAll12Phase 3United States
2NCT01940094
(ClinicalTrials.gov)
February 20146/9/2013The Assessment of Prednisone In Remission Trial - Centers of Excellence ApproachThe Assessment of Prednisone In Remission Trial (TAPIR) - Centers of Excellence ApproachGranulomatosis With PolyangiitisDrug: 5 mg Prednisone;Drug: 0 mg PrednisoneUniversity of PennsylvaniaNational Heart, Lung, and Blood Institute (NHLBI);National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS);Office of Rare Diseases (ORD);National Center for Advancing Translational Science (NCATS);Rare Diseases Clinical Research NetworkRecruiting18 YearsN/AAll159Phase 3United States;Canada